Login Register Cart 0
Generic placeholder image

Current Cosmetic Science

Editor-in-Chief

ISSN (Print): 2666-7797
ISSN (Online): 2666-7800

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Electrochemotherapy in the Treatment of Kaposi’s Sarcoma: A Single Centre Cohort Study and a Comparison with the Literature Data

Author(s): Edoardo Cammarata, Roberto Giorgione, Marco Andreassi, Chiara Airoldi and Paola Savoia*

Volume 1, Issue 1, 2022

Published on: 05 August, 2021

Article ID: e050821195286 Pages: 8

DOI: 10.2174/2666779701666210805100043

Abstract

Background: Kaposi's sarcoma (KS) is a tumor of endothelial derivation, which primarily affects the skin and is mainly related to the type 8 Human Herpesvirus (HHV8). Its onset is favored by immunosuppression, although the most common form is the classic or sporadic KS mainly developing in elderly men of Mediterranean and Eastern European origin. Different therapeutic options are available, depending on the clinical variant, progression pattern, and comorbidities. The treatment of localized forms includes surgical excision, laser treatment, cryosurgery, radiotherapy, imiquimod 5%, and intra-lesion injection of cytotoxic drugs; on the other hand, the treatment of widespread disease encompasses radiotherapy and chemotherapy.

Methods: In this scenario, Electrochemotherapy (ECT), has shown to be an effective alternative to traditional treatment for disseminated KS skin lesions. The rationale of ECT relies on the local application of short, high-voltage electric pulses, able to open transient pores in the cell membrane (reversible electroporation that increases the delivery of some poorly permeant cytotoxic agents into the cytosol.

Results: Herein, we performed a retrospective analysis on 9 KS patients treated with ECT at our center between June 2016 and January 2020. The rate of Complete Response (CR) was 77.8% after the first cycle of treatment and 88.9% after the second course, with an overall response (OR) of 100%.

Conclusion: Sustained local control of treated lesions was present in 77.8% of patients 6 months after the treatment and all of them reported only mild local toxicity, together with an excellent functional and cosmetic outcome, in agreement with data obtained from the comparison with the recent literature.

Keywords: Electrochemotherapy, bleomycin, kaposi’s sarcoma, treatment, effectiveness, cosmetic outcomes.

Graphical Abstract

[1]
Radu, O.; Pantanowitz, L. Kaposi sarcoma. Arch. Pathol. Lab. Med., 2013, 137(2), 289-294.
[http://dx.doi.org/10.5858/arpa.2012-0101-RS] [PMID: 23368874]
[2]
Curtiss, P.; Strazzulla, L.C.; Friedman-Kien, A.E. An Update on Kaposi’s Sarcoma: Epidemiology, Pathogenesis and Treatment. Dermatol. Ther. (Heidelb.), 2016, 6(4), 465-470.
[http://dx.doi.org/10.1007/s13555-016-0152-3] [PMID: 27804093]
[3]
Goncalves, P.H.; Ziegelbauer, J.; Uldrick, T.S.; Yarchoan, R. Kaposi sarcoma herpesvirus-associated cancers and related diseases. Curr. Opin. HIV AIDS, 2017, 12(1), 47-56.
[http://dx.doi.org/10.1097/COH.0000000000000330] [PMID: 27662501]
[4]
Bishop, B.N.; Lynch, D.T. Kaposi Sarcoma.StatPearls; StatPearls Publishing: Treasure Island, FL, 2020.
[5]
Régnier-Rosencher, E.; Guillot, B.; Dupin, N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J. Am. Acad. Dermatol., 2013, 68(2), 313-331.
[http://dx.doi.org/10.1016/j.jaad.2012.04.018] [PMID: 22695100]
[6]
Schneider, J.W.; Dittmer, D.P. Diagnosis and treatment of kaposi sarcoma. Am. J. Clin. Dermatol., 2017, 18(4), 529-539.
[http://dx.doi.org/10.1007/s40257-017-0270-4] [PMID: 28324233]
[7]
Marty, M.; Sersa, G.; Garbay, J.R.; Gehl, J.; Collins, C.G.; Snoj, M.; Billard, V.; Geertsen, P.F.; Larkin, J.O.; Miklavcic, D.; Pavlovic, I.; Paulin-Kosir, S.M.; Cemazar, M.; Morsli, N.; Soden, D.M.; Rudolf, Z.; Robert, C.; O’Sullivan, G.C.; Mir, L.M. Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Pro-cedures of Electrochemotherapy) Study. Eur. J. Cancer, Suppl., 2006, 4(11), 3-13.
[http://dx.doi.org/10.1016/j.ejcsup.2006.08.002]
[8]
Bertino, G.; Sersa, G.; De Terlizzi, F.; Occhini, A.; Plaschke, C.C.; Groselj, A.; Langdon, C.; Grau, J.J.; McCaul, J.A.; Heuveling, D.; Cemazar, M.; Strojan, P.; de Bree, R.; Leemans, C.R.; Wessel, I.; Gehl, J.; Benazzo, M. European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer. Eur. J. Cancer, 2016, 63, 41-52.
[http://dx.doi.org/10.1016/j.ejca.2016.05.001] [PMID: 27267144]
[9]
Campana, L.G.; Testori, A.; Curatolo, P.; Quaglino, P.; Mocellin, S.; Framarini, M.; Borgognoni, L.; Ascierto, P.A.; Mozzillo, N.; Guida, M.; Bucher, S.; Rotunno, R.; Marenco, F.; De Salvo, G.L.; De Paoli, A.; Rossi, C.R.; Bonadies, A. Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors. Eur. J. Surg. Oncol., 2016, 42(12), 1914-1923.
[http://dx.doi.org/10.1016/j.ejso.2016.06.399] [PMID: 27424789]
[10]
Curatolo, P.; Quaglino, P.; Marenco, F.; Mancini, M.; Nardò, T.; Mortera, C.; Rotunno, R.; Calvieri, S.; Bernengo, M.G. Electrochemothera-py in the treatment of Kaposi sarcoma cutaneous lesions: A two-center prospective phase II trial. Ann. Surg. Oncol., 2012, 19(1), 192-198.
[http://dx.doi.org/10.1245/s10434-011-1860-7] [PMID: 21822561]
[11]
Bonadies, A.; Bertozzi, E.; Cristiani, R.; Govoni, F.A.; Migliano, E. Electrochemotherapy in skin malignancies of head and neck cancer pa-tients: Clinical efficacy and aesthetic benefits. Acta Derm. Venereol., 2019, 99(13), 1246-1252.
[http://dx.doi.org/10.2340/00015555-3341] [PMID: 31612236]
[12]
Quaglino, P.; Matthiessen, L.W.; Curatolo, P.; Muir, T.; Bertino, G.; Kunte, C.; Odili, J.; Rotunno, R.; Humphreys, A.C.; Letulé, V.; Maren-co, F.; Cuthbert, C.; Albret, R.; Benazzo, M.; De Terlizzi, F.; Gehl, J. Predicting patients at risk for pain associated with electrochemothera-py. Acta Oncol., 2015, 54(3), 298-306.
[http://dx.doi.org/10.3109/0284186X.2014.992546] [PMID: 25591818]
[13]
Fan, J.W.; Wan, X.F.; Yi, B.; Dong, J.C.; Abulize, P. Clinicopathological analysis of 114 cases of typical Kaposi’s sarcoma in Xinjiang Uy-gur autonomous region, China. Mol. Med. Rep., 2017, 16(4), 5495-5498.
[http://dx.doi.org/10.3892/mmr.2017.7283] [PMID: 28849228]
[14]
Starita, N.; Di Monta, G.; Cerasuolo, A.; Marone, U.; Anniciello, A.M.; Botti, G.; Buonaguro, L.; Buonaguro, F.M.; Tornesello, M.L. Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma. Infect. Agent. Cancer, 2017, 12, 35.
[http://dx.doi.org/10.1186/s13027-017-0147-4] [PMID: 28649271]
[15]
Di Monta, G.; Caracò, C.; Benedetto, L.; La Padula, S.; Marone, U.; Tornesello, M.L.; Buonaguro, F.M.; Simeone, E.; Ascierto, P.A.; Moz-zillo, N. Electrochemotherapy as “new standard of care” treatment for cutaneous Kaposi’s sarcoma. Eur. J. Surg. Oncol., 2014, 40(1), 61-66.
[http://dx.doi.org/10.1016/j.ejso.2013.09.002] [PMID: 24075826]
[16]
Latini, A.; Bonadies, A.; Trento, E.; Bultrini, S.; Cota, C.; Solivetti, F.M.; Ferraro, C.; Ardigò, M.; Amorosi, B.; Palamara, G.; Bucher, S.; Giuliani, M.; Cordiali-Fei, P.; Ensoli, F.; Di Carlo, A. Effective treatment of Kaposi’s sarcoma by electrochemotherapy and intravenous bleomycin administration. Dermatol. Ther. (Heidelb.), 2012, 25(2), 214-218.
[http://dx.doi.org/10.1111/j.1529-8019.2012.01437.x] [PMID: 22741941]
[17]
Skarlatos, I.; Kyrgias, G.; Mosa, E.; Provatopoulou, X.; Spyrou, M.; Theodorou, K.; Lepouras, A.; Gounaris, A.; Koukourakis, M. Elec-trochemotherapy in cancer patients: First clinical trial in Greece. In Vivo, 2011, 25(2), 265-274.
[PMID: 21471545]
[18]
Rotunno, R.; Campana, L.G.; Quaglino, P.; de Terlizzi, F.; Kunte, C.; Odili, J.; Gehl, J.; Ribero, S.; Liew, S.H.; Marconato, R.; Brizio, M.; Curatolo, P. Electrochemotherapy of unresectable cutaneous tumours with reduced dosages of intravenous bleomycin: Analysis of 57 pa-tients from the International Network for Sharing Practices of Electrochemotherapy registry. J. Eur. Acad. Dermatol. Venereol., 2018, 32(7), 1147-1154.
[http://dx.doi.org/10.1111/jdv.14708] [PMID: 29178483]
[19]
Falk, H.; Matthiessen, L.W.; Wooler, G.; Gehl, J. Calcium electroporation for treatment of cutaneous metastases; A randomized double-blinded phase II study, comparing the effect of calcium electroporation with electrochemotherapy. Acta Oncol., 2018, 57(3), 311-319.
[http://dx.doi.org/10.1080/0284186X.2017.1355109] [PMID: 28816072]
[20]
Groselj, A.; Bosnjak, M.; Strojan, P.; Krzan, M.; Cemazar, M.; Sersa, G. Efficiency of electrochemotherapy with reduced bleomycin dose in the treatment of nonmelanoma head and neck skin cancer: Preliminary results. Head Neck, 2018, 40(1), 120-125.
[http://dx.doi.org/10.1002/hed.24991] [PMID: 29130624]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy